Incannex Healthcare announces a positive Pre-Investigational New Drug Application meeting with the FDA concerning IHL-42X, a compound for treating sleep apnoea.
MindMed reports results for Q1 2022. Progress on clinical trials. Used $12.9 million cash in previous quarter. Cash balance of $120.5 million as of March 31, 2022.
Optimi Health announces the acquisition of a diverse catalogue of psilocybin and functional mushroom strains intended for cultivation.
atai Life Sciences reports Q1 for 2022: clinical trials advancing and cash position of $335 million.
Red Light Holland announces successfully importing its psilocybin microdose packs from the Netherlands into Canada.
Numinus Wellness announces Health Canada approval of its application to use psilocybin-assisted therapy for treatment-resistant depression (TRD).
Field Trip launches a telehealth version of its ketamine-assisted therapy, via a partnership with Nue Life Health.
Mindset Pharma announces initial planning of its Phase 1 clinical trials for its first family of novel molecules.
MindMed announces it will host a webinar on substance abuse disorders and withdrawal management that includes prominent experts in this field.
Revitalist Lifestyle and Wellness reports strong month-over-month and year-over-year revenue gains from its ketamine clinic operations.